Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now?

International Journal of Experimental Pathology

Volumn 79, Issue 6, 1998, Pages 339-346

  Leenders, William P J ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Antagonist; Antiangiogenesis; Cancer therapy; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CONTROLLED STUDY; DNA TRANSFER; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE DISRUPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032437411     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.1998.00086.x     Document Type: Review

References (67)

1. ARBISER J.L., MOSES M.A., FERNANDEZ C.A. ET AL. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94, 861-866.
2. 121. Cancer Res. 55, 5296-5301.
3. BARINAGA M. (1997) Designing therapies that target tumor blood vessels. Science 275, 482-484.
4. BENJAMIN LE. & KESHET E. (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 94, 8761-8766.
5. BISCHOFF J. (1997) Cell adhesion and angiogenesis. J. Clin. Invest. 99, 373-376.
6. BORGSTRÖM P., HILLAN K.J., SRIRAMARAO P. & FERRARA N. (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032-4039.
7. BOUCK N. (1996) P53 and angiogenesis. Biochim. Biophys. Acta 1287, 63-66.
8. CAO Y., CHEN H., ZHOU L. ET AL. (1996) Heterodimers of placenta growth factor/vascular endothelial growth factor. J. Biol. Chem. 271, 3154-3162.
9. CHENG S.-Y., HUANG S., NAGAME M. ET AL. (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 93, 8502-8507.
10. CLAFFEY P.C., SENGER D. & SPIEGELMAN B.M. (1995) Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim. Biophys. Acta 1246, 1-9.
11. CLAFFEY K., BROWN L., DEL AGUILA L. ET AL. (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56, 172-181.
12. CLAUSS M., WEICH H., BREIER G. ET AL. (1996) The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J. Biol. Chem. 271, 17629-17634.
13. D'ANGELO G., STRUMAN I., MARTIAL J. & WEINER R.I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16 kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA 92, 6374-6378.
14. DISALVO J., BAYNE M.L., CONN G. ET AL. (1995) Purification and characterization of a naturally occurring vascular endothelial growth factor: placenta growth factor heterodimer. J. Biol. Chem. 270, 7717-7723.
15. ELLIS L.M. & FIDLER I.J. (1996) Angiogenesis and metastasis. Eur J. Cancer 32A, 2451-2460.
16. ELLIS L.M., STALEY C.A., LIU W. ET AL. (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem. 273, 1052-1057.
17. FINKEL T. & EPSTEIN S.E. (1995) Gene therapy for vascular disease. FASEB J. 9, 843-851.
18. FLOTTE T.R. & CARTER B.J. (1995) Adeno-associated virus vectors for gene therapy. Gene Ther. 2, 356-362.
19. FOLKMAN J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6.
20. FONG G.-H., ROSSANT J., GERTSENSTEIN M. & BREITMAN M.L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70.
21. FORSYTHE J.A., JIANG B.-H., IYER N.V. ET AL. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604-4613.
22. FUH G., LI B., CROWLEY C., CUNNINGHAM B. & WELLS J.A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197-11204.
23. GENGRINOVITCH S., GREENBERG S.M., COHEN T. ET AL. (1995) Platelet-factor 4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. 270, 15059-15065.
24. HANAHAN D. & FOLKMAN J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
25. HARRIS A.L. (1997) Antiangiogenesis for cancer therapy. Lancet 349(Supl. II), 13-15.
26. HATVA E., KAIPAINEN A., MENTULA P. ET AL. (1995) Expression of endothelial cell-specific receptor kinases and growth factors in human brain tumors. Am. J. Path. 146, 368-378.
27. HOUCK K.A., LEUNG D.W., ROWLAND A.M., WINER J. & FERRARA N. (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031-26037.
28. IKEDA E., ACHEN M.G., BREIER G. & RISAU W. (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270, 19761-19766.
29. 165 in patient with ischaemic limb. The Lancet 348, 370-374.
30. JIN KIM K., LI B., WINER J., AHMANINI M., GILLETT N., PHILIPS H.S. & FERRARA N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
31. JOUKOV V., PAJUSOLA K., KAIPANEN A. ET AL. (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO J. 15, 290-298.
32. KECK R.G., BERLEAU L., HARRIES R. & KEYT B.A. (1997) Disulfide structure of the heparin binding domain in vascular endothelial growth factor: Characterization of posttranslational modifications in VEGF. Arch. Biochem. Biophys. 344, 103-113.
33. KENDALL R.L. & THOMAS K.A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705-10709.
34. KENDALL R.L., WANG G. & THOMAS K.A. (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Comm 226, 324-328.
35. KEYT B.A., BERLEAU L.T., NGUYEN H.V. ET AL. (1996a) The carboxy-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788-7795.
36. KEYT B.A., NGUYEN H.V., BERLEAU L.T. ET AL. (1996b) Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors. J. Biol. Chem. 271, 5638-5646.
37. KIM LEE SIM B., O'REILLY M., LIANG H. ET AL. (1997) A recombinant angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57, 1329-1334.
38. KLAGSBRUN M. (1991) Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J. Cell Biochem. 47, 199-200.
39. KONDO S., ASANO M. & SUZUKI H. (1993) Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem. Biophys. Res. Comm 194, 1234-1241.
40. KROLL J. & WALTENBERGER J. (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521-32527.
41. LEVY A.P., LEVY N.S. & GOLDBERG M.A. (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271, 2746-2753.
42. MAXWELL P.M., DACHS G.U., GLEADLE J.M. ET AL. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
43. MILLAUER B., SHAWVER L.K., PLATE K.H., RISAU W. & ULLRICH A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
44. MILLAUER B., LONGHI M.P., PLATE K.H. ET AL. (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620.
45. MUKHOPADHYAY D., TSOKIAS L., ZHOLI X.-M., FOSTER D., BRUGGE J.S. & SUKHATME V.P. (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581.
46. MUKHOPADHYAY D., KNEBELMANN B., COHEN H.T., ANANTH S. & SUKHATME V.S. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol. 17, 5629-5639.
47. MUKHOPADHYAY D., NAGY J.A., MANSEAU E.J. & DVORAK H.F. (1998) Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res. 58, 1278-1284.
48. MULLER Y.A., LI B., CHRISTINGER H.W., WELLS J.A., CUNNINGHAM B.C. & DE VOS A.M. (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. USA 94, 7192-7197.
49. O'REILLY M., BOEHM T., SHING Y. ET AL. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
50. OKADA F., RAK J.W., ST. CROIX B. ET AL. (1998) Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 3609-3614.
51. OLOFSSON B., PAJUSOLA K., KAIPAINEN A. ET AL. (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA 93, 2576-2581.
52. ORLANDINI M., MAHCONCINI L., FERUZZI R. & OLIVIERO S. (1996) Identification of a c-fos induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA 93, 11675-11680.
53. PARK J., CHEN H., WINER J., HOUCK K. & FERRARA N. (1994) Placenta Growth Factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654.
54. PLOUET J., MORO F., BERTAGNOLLI S. ET AL. (1997) Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 272, 13390-13396.
55. PÖTGENS A.J., LUBSEN N.H., VAN ALTENA M.C. ET AL. (1994) Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J. Biol. Chem. 269, 32879-32885.
56. PÖTGENS A.J., VAN ALTENA M.C., LUBSEN N.H., RUITER D.J. & DE WAAL R.M.W. (1996) Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am. J. Path. 148, 1203-1217.
57. SALEH M., STACKER S.A. & WILKS A.F. (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393-401.
58. SHALABY F., ROSSANT J., YAMAGUCHI T.P. ET AL. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
59. SIEMEISTER G., SCHIRNER M., REUSCH P., BARLEON B., MARME D. & MARTINY-BARON G. (1998) An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl. Acad. Sci. USA 95, 4625-4629.
60. SOKER S., FIDDER H., NEUFELD G. & KLAGSBRUN M. (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon-7 encoded domain. J. Biol. Chem. 271, 5761-5767.
61. 165. J. Biol. Chem. 272, 31582-31588.
62. TAKAHASHI Y., KITADAI Y., BUCANA C., CLEARY K. & ELLIS L. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55, 3964-3968.
63. VAN BELLE E., WITZENBICHLER B., CHEN D. ET AL. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation 97, 381-390.
64. VARNER J.A., BROOKS P.C. & CHERESH D.A. (1995) Review: the integrin alpha v beta 3: angiogenesis and apoptosis. Cell Adhes. Commun. 3, 367-374.
65. VIGLIETTO G., MAGLIONE D., RAMBALDI M. ET AL. (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11, 1569-1579.
66. WALSH T.P. & GRANT G.H. (1997) Computer modelling of the receptor-binding domains of VEGF and PIGF. Protein Engineering, 10, 389-398.
67. WANG M., LIU Y.E., GREEN J. ET AL. (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14, 2767-2774.